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The presence of an altered renal function in essential hypertension, advanced heart failure
(HF) and after a myocardial infarction (MI) is associated with higher cardiovascular
morbidity and mortality. Indices of altered renal function (e.g., microalbuminuria, increased
serum creatinine concentrations, decrease in estimated creatinine clearance or overt protein-
uria) are independent predictors of cardiovascular morbidity and mortality in any of the three
clinical situations. These parameters should then be routinely evaluated in clinical practice.
These facts have several therapeutic implications. First, although there is no evidence-based
information on the level of blood pressure that confers optimal renal protection, levels
substantially lower than past recommendations are advisable. Second, hypertensive kidney
damage should be prevented by early treatment of hypertensive patients, particularly those
with microalbuminuria. Finally, to avoid further aggravation of high cardiovascular risk,
antihypertensive agents devoid of unwanted metabolic side effects should be used for the
treatment of hypertensive vascular damage. In HF, the combination of an angiotensin-
converting enzyme (ACE) inhibitor and a beta-blocker seem to be the most renoprotective.
Renal outcome is also improved by ACE inhibition after an MI. Finally, renal and
cardiovascular outcome seem to run in parallel in all these situations. (J Am Coll Cardiol
2001;38:1782–7) © 2001 by the American College of Cardiology
Cardiovascular mortality is profoundly affected by the pres-
ence of advanced renal failure. In patients undergoing main-
tenance hemodialysis, cardiovascular mortality is approximately
3 to 20 times that of age-matched nonuremic control subjects
(1). The increased mortality is associated with a higher fre-
quency of conditions such as myocardial infarction (MI), left
ventricular (LV) hypertrophy, and congestive heart failure
(CHF). Hypervolemia, arterial hypertension, and dyslipidemia
are among the most relevant causes leading to increased
cardiovascular morbidity and mortality in advanced renal fail-
ure. Recent analyses have shown that renal function is a major
determinant of cardiovascular outcome in patients with essen-
tial hypertension (2–4) or with heart failure (HF) (5,6) in the
absence of primary renal disease. A minor increase in serum
creatinine above normal values and, conversely, a slight de-
crease in creatinine clearance were powerful predictors of future
cardiovascular death. This brief review summarizes the avail-
able evidence in this field, which is highly relevant because
renal data are easy to obtain and provide valuable information.
DIAGNOSIS OF RENAL
DAMAGE IN CLINICAL PRACTICE
The diagnosis of renal dysfunction in patients with different
forms of cardiovascular disease is based on two findings:
1) elevated serum creatinine or a decrease in glomerular
filtration rate (GFR), usually measured as creatinine clear-
ance and/or 2) the detection of an elevated urinary excretion
of albumin below (microalbuminuria, 30 to 300 mg/day)
or above (macroalbuminuria, 300 mg/day), the usual
laboratory methods to detect proteinuria. Mild renal insuf-
ficiency has recently been defined as serum creatinine (SCr)
values 1.5 mg/dl (132 mol/l) in men and 1.4 mg/dl
(123 mol/l) in women (7,8), or by the finding of estimated
creatinine clearance values below 60 to 70 ml/min (2,6).
Whereas an elevated SCr concentration points to a reduced
GFR, an increased rate of albumin or protein excretion
points to a derangement in the glomerular filtration barrier
(9). Microalbuminuria has been shown to correlate with the
presence of nephrosclerosis (10), while the presence of
proteinuria generally indicates the existence of established
renal parenchymatous damage (9). On the other hand, the
finding of a SCr value within the normal range can be
accompanied by a diminished GFR value, particularly in
elderly patients (11). An estimate of creatinine clearance in
the absence of 24-h urine collection can be obtained based
on prediction equations corrected for age, gender and body
size (8). Finally, hyperuricemia (defined as a serum uric acid
level in excess of 7 mg/dl) is frequently seen in untreated
hypertensives and has also been shown to correlate with the
existence of nephrosclerosis (12).
RENAL FUNCTION AS A PREDICTOR OF
CARDIOVASCULAR RISK IN ESSENTIAL HYPERTENSION
The kidney and high blood pressure (BP) are closely related.
A defective capacity to handle the dietary sodium normally
resulting from intrinsic renal abnormalities (13) or an
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inadequate response of the kidney to an extrarenal mecha-
nism triggering the hypertensive process (14), are among
the most important mechanisms in the initiation and
maintenance of essential hypertension. Furthermore, renal
vasoconstriction is found at the initial stages of essential
hypertension, and this is reversed by the administration of
calcium channel blockers and angiotensin-converting en-
zyme (ACE) inhibitors (14). In more advanced stages of the
disease, renal vascular resistance is permanently elevated as
a consequence of structural lesions of the renal vessels
(nephrosclerosis). Such structural damage may underlie the
clinical finding of microalbuminuria (10), or the develop-
ment of overt proteinuria, as well as an increase in SCr or a
decrease in creatinine clearance.
Before antihypertensive treatment became available, renal
involvement was frequent in patients with primary hyper-
tension. Perera (15) found that proteinuria was present in
42%, and chronic renal failure in 18%, in a series of 500
untreated patients followed until death by the investigator.
In this series, life expectancy after the onset of renal
involvement was reported to be no more than five to seven
years. With the advent of antihypertensive therapy, cardio-
vascular and renal prognosis of hypertensive patients im-
proved dramatically. There is agreement that renal progno-
sis is excellent when hypertension is treated. Today, only a
small percentage of treated hypertensive patients, about 3%,
develop chronic renal failure defined by SCr values (2).
However, this percentage has been found to reach 10.7% of
patients included in the Heart Outcomes Prevention Eval-
uation (HOPE) study (4), about 8% of the population
included in the Framingham Heart Study (8), and 3% in the
general U.S. population according to National Health And
Nutrition Examination Survey (NHANES) III data (16).
The results of this survey also demonstrate that such a high
prevalence is not explained by the simultaneous presence of
diabetes but that it is related to inadequate treatment of
high BP (16). When GFR is determined by estimated
creatinine clearance the percentage of hypertensive patients
with a diminished renal function was 13% in the Hyper-
tension Optimal Treatment (HOT) study (2), and36% in
the HOPE study (4). Interestingly, this parameter is dimin-
ished in 50% of the U.S. population above 50 years of age
(17). These data help explain the progressive increase in
prevalence of nephrosclerosis as a cause of end-stage renal
failure in patients entering dialysis programs both in the
U.S. and in Europe (18,19).
In the Hypertension Detection and Follow-up Program
trial (20), the presence of elevated SCr values (1.7 mg/dl)
at baseline was found to be a very potent predictor for five-
and eight-year all-cause mortality. In the Cardiovascular
Health Study, baseline SCr values 1.7 mg/dl were asso-
ciated with a 70% increase in risk for all-cause mortality in
elderly men and women followed for five years (21). The
risk conferred was similar to that associated with the
presence of CHF at baseline. Data from the HOT study (2)
have confirmed these findings, demonstrating that SCr
values above the cutoff point for mild renal insufficiency
predict an elevated cardiovascular risk even when BP control
is excellent. In fact, in the HOT study, SCr values were the
most powerful predictor of mortality, stronger than any of
the known accompanying risk factors (2). The investigators
also assessed the prognostic value of a diminished creatinine
clearance, as estimated by the Cockcroft and Gault formula
(8). Values 60 ml/min were associated with a significantly
higher cardiovascular risk (2). In the general population, the
presence of an elevated SCr concentration is also associated
with a high prevalence of cardiovascular disease (7), as in the
case of essential hypertension. This has been attributed to
the fact that elevated SCr concentrations coexist with
several other cardiovascular risk factors (7,22).
The relevance of proteinuria for cardiovascular prognosis
in the community was documented by the Framingham
Heart Study (23). The presence of proteinuria in patients
with treated essential hypertension varies between 4% and
16% in different series of treated hypertensive patients (24).
The International Nifedipine GITS Study: Intervention as
a Goal in Hypertension Treatment (INSIGHT) study (3)
compared the capacity of a long-acting dihydropiridine and
a diuretic to diminish cardiovascular events and death in
essential hypertension. This study assessed the role of
proteinuria as a risk factor. Analysis of the different risk
factors revealed that proteinuria conferred a very powerful
risk (3).
Attention has recently been drawn to microalbuminuria
and its relevance as a predictor of cardiovascular disease
(25). Its prevalence varies between 20% and 30% of un-
treated patients and up to 25% in treated patients. Very
recently, it has been shown that the presence of microalbu-
minuria in primary hypertension carries with it an elevated
cardiovascular risk (4,26). According to a persuasive hy-
pothesis, microalbuminuria constitutes the renal expression
of a generalized disorder characterized by increased endo-
thelial permeability. This hypothesis provides an explana-
tion for the link between increased urinary albumin excre-
tion and elevated cardiovascular risk (25). Some preliminary
data indicate that, in primary hypertension, microalbumin-
uria is also a predictor of progressive deterioration of renal
function in primary hypertension (22,27).
Some data indicate that nephrosclerosis, often found in
hypertensive patients, is associated with atherosclerosis of
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the large arteries. Nephrosclerosis is characterized by hya-
linization of arterioles and fibroplastic intimal thickening of
small arteries. Interestingly, in patients with coronary heart
disease, hyalinization of renal arterioles is more marked than
in matched control subjects (28). Conversely, in autopsy
studies the presence of hyalinization in the renal arterioles is
a marker for the presence of advanced coronary atheroscle-
rosis in otherwise asymptomatic young individuals (29).
On the other hand, in individuals with primary renal
disease, even very mild degrees of renal failure show an
increase in cardiovascular risk, demonstrated by the finding
of disturbed lipoprotein (a) concentrations (30) as well as
the presence of insulin resistance (31) in proteinuric patients
with normal or slightly reduced GFR levels. In early stages
of primary renal disease, with GFR values ranging from 60
to 80 ml/min, an increased oxidative stress has also been
demonstrated (32), as well as an increment in pulse wave
velocity, indicative of diminished arterial compliance (33).
The presence of mild renal insufficiency in hypertensives is
accompanied by higher initial levels of both systolic and
diastolic BP, a predominantly male gender, higher initial
levels of serum uric acid and triglycerides, and lower levels of
high-density lipoprotein cholesterol (22). A multivariate
logistic regression analysis identified systolic and diastolic
BP, as well as serum uric acid and triglycerides, as indepen-
dent predictors for the development of nephrosclerosis. One
study (34) showed that insulin resistance in mildly hyper-
tensive subjects is associated with renal injury as a result of
impaired renal hemodynamics (i.e., elevation of glomerular
filtration fraction and glomerular hyperfiltration). All these
findings are accompanied by the absence of a nocturnal
decrease in BP, which also contributes to an increasing risk
in patients in the initial stages of renal insufficiency (35,36).
The data indicate that even minor derangements of renal
function are associated with metabolic alterations, show an
increase in cardiovascular risk factors, and promote progres-
sion of atherosclerosis.
On the other hand, hyperuricemia has been shown to
predict a poor cardiovascular outcome in hypertensive pa-
tients (37). As previously stated, elevated serum uric acid
levels reflect the presence of nephrosclerosis (12), which is
frequently accompanied by a diminution in GFR. This fact
could jeopardize the predictive capacity of hyperuricemia in
favor of that of a diminished renal function (38).
RENAL FUNCTION AS A
PREDICTOR OF CARDIOVASCULAR RISK IN HF
Alterations in renal function play a key role in the patho-
physiology of HF and are influenced by the treatment of
this syndrome. Adequacy of renal function may be a primary
determinant of compensation in patients with HF, and
therapy capable of improving renal function may delay
progression of HF (6,39).
Arterial underfilling is one major factor among the
complex mechanisms that lead to renal sodium and water
retention in HF (40). Decreased “fullness of the arterial
circulation” is sensed by the kidney and erroneously inter-
preted as due to volume depletion. The kidney paradoxically
retains sodium despite the increase of extracellular volume
in an attempt to restore arterial filling. In parallel, neuro-
humoral systems are activated (e.g., the renin-angiotensin-
aldosterone system or the sympathetic nervous system),
vasopressin is released and endothelin production is en-
hanced (40). Interestingly, even in patients with only mild
ventricular dysfunction, in whom cardiac output is reduced
by 20%, renal perfusion was markedly reduced (i.e., by 50%)
(41). This finding reflects intense renal vasoconstriction
even in the initial stages of CHF (42), which further
facilitates the compensatory sodium and water retention to
restore arterial filling and maintain BP within a normal
range.
The renal capacity to maintain sodium balance in re-
sponse to a high sodium intake is altered early on in HF
(43), and the renal functional reserve is reduced even when
the ejection fraction is still normal (43). In more advanced
stages of HF, both renal plasma flow and GFR decrease
(44). Progressive renal dysfunction is a frequent complica-
tion in HF. It is the net result of progressively decreased
cardiac output and renal perfusion pressure, as well as renal
vasoconstriction facilitated by neurohumoral activation. Re-
cent data have shown that these changes in GFR correlate
better with neurohumoral activation than with the left
ventricular ejection fraction (LVEF) (5). Advanced age,
frequently present in patients with HF, predisposes to the
decrease in renal function, as does a history of hypertension
or MI (45).
In HF, decreased renal function (i.e., a low creatinine
clearance) is associated with increased mortality (5,6). In
fact, impaired renal function is a stronger predictor than
impaired cardiac function (LVEF and New York Heart
Association functional class) (5).
RENAL FUNCTION AS A
PREDICTOR OF CARDIOVASCULAR
RISK IN VASCULAR DISEASE AND AFTER MI
Baseline renal function measured as SCr or estimated
creatinine clearance has shown to be an independent pre-
dictor of survival in patients with acute MI (46,47). Esti-
mated creatinine clearance is a powerful predictor of both
short- and long-term events in patients admitted to coro-
nary care units. Graded increases in the relative risk for atrial
and ventricular arrhythmias, heart block, asystole, develop-
ment of pulmonary congestion, and cardiogenic shock were
observed by McCullough et al. (48) in parallel with graded
decreases in renal function. The investigators concluded
that patients with estimated creatinine clearance values
46.2 ml/min had a higher risk for in-hospital and post-
discharge mortality.
The presence of a diminished renal function does not
preclude success rates in candidates for percutaneous coro-
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nary revascularization but is accompanied by an increased
rate of major events during both hospitalization long-term
follow-up (49). Chronic renal failure is associated with a
particularly high risk of further deterioration of renal func-
tion within 48 h of interventional coronary procedures. Such
a decline is accompanied by a significantly poorer outcome,
especially if dialysis is required (50). In diabetic patients,
particularly when they have proteinuria, a similarly poor
outcome has been described after isolated artery bypass
grafting (51).
The albumin excretion rate has been shown to increase
during MI, and this increase yields prognostic information
additional to that provided by clinical or echocardiographic
evaluation of LV performance (52). In fact, the albumin
excretion rate was a better predictor of in-hospital mortality
than the Killip class or the echocardiographic LVEF.
RENAL PROTECTION AND CARDIOVASCULAR DISEASE
Strict BP control is necessary to avoid renal damage in
primary hypertension. Two issues arise if one tries to achieve
maximum improvement in the renal prognosis of hyperten-
sive patients. The first is the BP goal, which affords the best
renal protection. According to one study (53), strict BP
control, obtained with different antihypertensive agents, did
not seem to further protect renal function. By contrast, strict
BP control slows the decay in renal function in patients with
primary renal disease and heavy proteinuria (54). This has
led to the recommendation that in patients with renal failure
and proteinuria in excess of 1 g/day, the BP goal should be
125/75 mm Hg (54). The results of the HOT study (2),
where patients were randomly allocated to one of three
different diastolic BP control goals (90, 85,
80 mm Hg), have confirmed the relevance of strict BP
control on cardiovascular protection and on indices of renal
damage (i.e., serum creatinine concentration).
Another issue is whether all antihypertensive drugs are
equally effective on renal outcome. Uniformly better out-
comes of renal function were obtained when ACE inhibi-
tors were compared to placebo in both diabetic (55) and
nondiabetic renal disease (56). In essential hypertension,
converting enzyme inhibitors reduced urinary albumin ex-
cretion more effectively as compared to diuretics, beta-
blockers, and calcium antagonists (57). Furthermore, in
hypertensive patients, ACE inhibitors facilitate the regres-
sion of remodeling of (58), and improve endothelial func-
tion in, resistance arterioles (59). A beneficial effect of this
class of drugs in renal outcome in nephrosclerosis when
compared to other therapies has also been suggested (60).
The presence of mild renal insufficiency (SCr 1.4 mg/dl)
was accompanied, in the HOPE study (4), by an enhanced
protective effect of ramipril to prevent cardiovascular death,
total death, and HF requiring hospitalization. Further
studies on renal and cardiovascular outcome are needed to
elucidate whether renal protection goes hand-in-hand with
cardiovascular protection and vice versa.
In HF, renal protection could constitute an important
aim of therapy. In the early stages of HF, the blockade of
angiotensin II, either with an ACE inhibitor or an angio-
tensin receptor blocker, was shown to correct abnormal
renal handling of sodium (43) and to restore the renal
functional reserve (44). This beneficial effect is probably
better explained by inactivation of the intrarenal renin-
angiotensin system than by a positive effect on the circulat-
ing system (61). In more advanced stages of HF, blockade of
angiotensin II was shown to improve the prognosis of those
patients in whom an improvement in LV function is
accompanied by a simultaneous improvement in renal func-
tion (61). It is true, however, that a decrease in renal
function is seen in about 10% to 25% of patients, usually
with advanced HF in whom maintenance of the GFR is
dependent upon angiotensin II (62,63). Advanced age, the
presence of atrial fibrillation and a low baseline GFR all
increase the risk of deterioration of renal function, which is
associated with a higher mortality after hospital discharge
(64,65). An improvement in renal function has been ob-
served when ACE inhibition was combined with beta-
blockade (65). Recent data obtained in patients with HF
treated with the vasopeptidase inhibitor omapatrilat (66)
look promising and may indicate that combined inhibition
of ACE and of neutral endopeptidase could be the best
therapy to protect the kidney in HF. Finally, the drop in
renal function that is frequently seen after an MI has been
shown to be counteracted by the administration of an ACE
inhibitor (45).
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